BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 631 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 631 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total value of $15,857.03. Following the sale, the executive vice president directly owned 349,755 shares in the company, valued at $8,789,343.15. This trade represents a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

BioLife Solutions Trading Up 1.6%

NASDAQ:BLFS traded up $0.40 during mid-day trading on Wednesday, reaching $25.01. The company’s stock had a trading volume of 296,709 shares, compared to its average volume of 445,500. The stock has a market cap of $1.20 billion, a P/E ratio of -357.23 and a beta of 1.93. The firm’s fifty day moving average price is $26.39 and its two-hundred day moving average price is $24.51. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BLFS. Invesco Ltd. grew its stake in shares of BioLife Solutions by 0.5% during the 3rd quarter. Invesco Ltd. now owns 3,599,444 shares of the medical equipment provider’s stock valued at $91,822,000 after acquiring an additional 18,666 shares during the period. Vanguard Group Inc. boosted its position in shares of BioLife Solutions by 2.4% in the third quarter. Vanguard Group Inc. now owns 2,967,518 shares of the medical equipment provider’s stock worth $75,701,000 after purchasing an additional 70,248 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in shares of BioLife Solutions in the first quarter worth $30,789,000. Ameriprise Financial Inc. increased its stake in shares of BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after purchasing an additional 109,959 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of BioLife Solutions by 2.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,003,383 shares of the medical equipment provider’s stock valued at $25,592,000 after purchasing an additional 20,175 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BLFS has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Finally, Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $30.75.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.